Business is booming for NextCure Inc., which took its first novel targeted immuno-oncology candidate into clinical development after raising a $93m Series B financing and finalizing a research collaboration with Eli Lilly & Co. that it says will feed both companies’ R&D pipelines.
NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.
More from Start-Ups & SMEs
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.
• By
The potential first-in-class antibody oligonucleotide conjugate could treat a form of the muscle wasting disease, and could be the first of Avidity’s trio of rare disease drugs to gain approval.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.